Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753952 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL29395053 | 0.89 | LTA4H (0.62) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL9393008 | 0.86 | RAB9A (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL8362464 | 0.83 | LTA4H (0.56) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL20353588 | 0.83 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL25266534 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL4609213 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL30427471 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL7618233 | 0.82 | LTA4H (0.61) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL15465921 | 0.81 | MAPT (0.62) | MEN1KMT2AMAPTCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432314-B1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE | PROBIODRUG AG (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9462793-B2 | Mouse carrying a knock-out mutation of the Qpct-gene | PROBIODRUG AG (DE) | 2016-10-11 | — | — | US | disclosed |
| US-9277737-B2 | Mouse models carrying a knock-out mutation of the QPCTL-gene | PROBIODRUG AG (DE) | 2016-03-08 | — | — | US | disclosed |
| US-20150150225-A1 | TRANSGENIC MOUSE EXPRESSING HUMAN ISOGLUTAMINYL CYCLOTRANSFERASE | PROBIODRUG, AG (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20130291133-A1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE | PROBIODRUG AG (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2238252-B1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE | PROBIODRUG AG (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120070444-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS | PROBIODRUG AG (DE) | 2012-03-22 | — | — | US | disclosed |
| US-8138311-B2 | Modified proteins, designer toxins, and methods of making thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2012028706-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS | PROBIODRUG AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2395095-A1 | In vivo screening models for treatment of Alzheimer's disease and other QPCT-related disorders | Probiodrug AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | PROBIODRUG AG (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008087197-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | PROBIODRUG AG (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-7285635-B2 | Modified proteins, designer toxins, and methods of making thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070036780-A1 | Reducing the antigenicity of a proteinaceous compound while maintaining the compound's biological activity | ROSENBLUM MICHAEL G | 2007-02-15 | — | — | US | disclosed |
| US-7083957-B2 | Modified proteins, designer toxins, and methods of making thereof | REASEARCH DEVELOPMENT FOUNDATION (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1406644-A4 | MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF | RES DEV FOUNDATION (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1406644-A2 | MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030176331-A1 | Modified proteins, designer toxins, and methods of making thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-09-18 | — | — | US | disclosed |
| WO-2002069886-A2 | MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-0382990-A1 | Strains of bacillus thuringiensis | PLANT GENETIC SYSTEMS, N.V. (BE) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070444-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS | NDUFAF1, UQCRC1, CPT1A | MEN1 3680/4885KMT2A 2022/4885MAPT 3663/4885 |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | QPCT, PCYT1A, PSEN2 | MEN1 3714/4885KMT2A 1486/4885MAPT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.